Latorraca Carolina de Oliveira Cruz, Pacheco Rafael Leite, Martimbianco Ana Luiza Cabrera, Pachito Daniela Vianna, Riera Rachel
MSc. Psychologist; Postgraduate Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP); and Assistant Researcher, Cochrane Brazil, São Paulo (SP), Brazil.
MD. Postgraduate Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP), and Assistant Researcher, Cochrane Brazil, São Paulo (SP), Brazil.
Sao Paulo Med J. 2018 Sep-Oct;136(5):472-478. doi: 10.1590/1516-3180.2018.0313210818. Epub 2018 Oct 22.
The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis on all Cochrane systematic reviews (SRs) that assessed the use of cannabinoids as a therapeutic approach.
Review of SRs, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP).
A broad search was conducted in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed the efficacy and safety of cannabinoids as a therapeutic approach. The results and key characteristics of all reviews included were summarized and discussed.
Eight SRs were included. They assessed the use of cannabinoids for the following types of conditions: neurological (two SRs), psychiatric (two SRs), rheumatological (one SR), infectious (one SR) and oncological (two SRs). There was moderate-quality evidence showing that the use of cannabinoids reduced nausea and vomiting among adults, compared with placebo. Additionally, there was moderate-quality evidence showing that there was no difference between cannabinoids and prochlorperazine regarding the number of participants who reported vomiting, in this same population.
This review identified eight Cochrane systematic reviews that provided evidence of unknown to moderate quality regarding the use of cannabinoids as a therapeutic intervention. Further studies are still imperative for solid conclusions to be reached regarding practical recommendations.
大麻素化合物的治疗效果一直是众多研究的核心。本研究对所有评估大麻素作为一种治疗方法的Cochrane系统评价（SRs）进行了综述。
在圣保罗联邦大学保罗医科大学循证医学学科进行的SRs综述。
在Cochrane系统评价数据库中进行广泛检索，以获取任何评估大麻素作为一种治疗方法的疗效和安全性的Cochrane SRs。对纳入的所有综述的结果和关键特征进行了总结和讨论。
纳入了8篇SRs。它们评估了大麻素在以下类型疾病中的应用：神经科（2篇SRs）、精神科（2篇SRs）、风湿科（1篇SR）、感染科（1篇SR）和肿瘤科（2篇SRs）。有中等质量的证据表明，与安慰剂相比，使用大麻素可减少成年人的恶心和呕吐。此外，有中等质量的证据表明，在同一人群中，在报告呕吐的参与者数量方面，大麻素与丙氯拉嗪之间没有差异。
本综述确定了8篇Cochrane系统评价，这些评价提供了关于大麻素作为一种治疗干预措施的质量未知至中等的证据。要就实际建议得出确凿结论，仍需要进一步研究。
